Table 2. Incidence and types of CD19 CAR-T cell therapy-related fatalities from systematic review and meta-analysis.

Variable	CD-19 Car-T (n=890)	Kymriah (n=201)	Yescarta (n=209)	P*
Deaths, No. (%)	33 (3.71%)	7 (3.48%)	9 (4.31%)	0.667
Type of fatal toxic effect
CRS	10 (30.30%)	0	2 (22.22%)	0.499
Nervous system disorders	6 (18.18%)	1 (14.29%)	1 (11.11%)	1
Infections and infestations	4 (12.12%)	1 (14.29%)	0	0.49
Blood and lymphatic system disorders	3 (9.09%)	2 (28.57%)	1 (11.11%)	0.617
Cardiac disorders	2 (6.06%)	1 (14.29%)	1 (11.11%)	1
Respiratory, thoracic and mediastinal disorders	2 (6.06%)	0	2 (22.22%)	0.499
Gastrointestinal disorders	2 (6.06%)	0	0	NA
Hepatobiliary disorders	1 (3.03%)	1 (14.29%)	0	1
unknown cause	3 (9.09%)	1 (14.29%)	2 (22.22%)	1

* Fatal toxic effects rates of Kymriah and Yescarta were compared using χ2 testing.